Vitiligo

Researchers emphasized the need for future studies to refine protocols and address economic barriers to combination therapy.

2024 saw significant progress in vitiligo treatments, including novel drugs, off-label uses, and updated pediatric guidelines for better outcomes.

Explore key insights and innovations in vitiligo from 2024, from treatment advances to patient-focused strategies.

LOV has unique clinical traits, epidemiology, and treatment responses compared to early-onset vitiligo, underscoring the need for a tailored management approach.

Regenerative methods such as cell therapy and platelet-rich plasma showed promising results in patient repigmentation.

Learn more about the in-depth topics covered in the November 2024 AD and Vitiligo supplement of Dermatology Times.

The panelist discusses the primary challenges in vitiligo repigmentation, including maintaining patient compliance through lengthy treatment courses and managing expectations around partial repigmentation outcomes, which require careful monitoring and ongoing patient education about realistic goals while assessing success through standardized documentation of even minimal improvements to inform treatment adjustments.

Andrew Alexis, MD, MPH, discusses how holistic management of vitiligo requires addressing both the physical and psychological impact through empathetic counseling and support groups while setting realistic treatment expectations and timelines with patients through clear communication about repigmentation goals, potential outcomes, and available therapeutic options.

Lisa Swanson, MD, discusses how telemedicine and digital health tools can aid in the management and follow-up care of pediatric patients with vitiligo by enabling remote monitoring, improving access to specialists, and facilitating patient engagement, while emerging research into vitiligo treatments may focus on developing therapies to halt or slow the progression of this autoimmune skin condition.

The panelist discusses advances in targeted therapies, including novel biologics and small molecules, as well as the development of personalized treatment approaches tailored to individual patient characteristics, which hold great promise for improving outcomes and enhancing the quality of life for children living with vitiligo in the future.

Lisa Swanson, MD, discusses providing educational resources and materials that explain vitiligo, dispel myths, and promote understanding.

In a Dermatology Times Case-Based Peer Perspective event, Terry Faleye, MPAS, PA-C, reviewed 2 cases of patients with vitiligo to discuss innovative treatments and emotional challenges with disease management.

Researchers stated the dual-action therapy could offer a promising approach to treat progressive non-segmental vitiligo.

VYNE Therapies announces that aNSV patients saw disease improvement without serious adverse effects.

Learn more about the in-depth topics covered in the October 2024 vitiligo supplement of Dermatology Times.

In a Dermatology Times Case-Based Roundtable event, Pearl E. Grimes, MD, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

In a Dermatology Times Case-Based Roundtable event, Ted Lain, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib.

Studies show conflicting serum levels of zinc and copper in vitiligo patients, indicating a need for further research.

In a Dermatology Times Case-Based Roundtable event, Chesahna Kindred, MD, MBA, FAAD, reviewed 2 cases of patients with vitiligo treated with ruxolitinib cream.

Investigators noted that further research is needed to monitor the prevalence of cardiovascular disease in patients with vitiligo.

Panelists discuss how treatment cycling strategies and optimal use of ruxolitinib can enhance the management of vitiligo, providing key takeaways for clinical practice.

In a Dermatology Times Case-Based Roundtable event, Andrew Alexis, MD, MPH, FAAD, reviewed 3 cases of patients with vitiligo treated with ruxolitinib cream.

Panelists discuss how their clinical experiences with topical ruxolitinib are shaping new treatment paradigms for vitiligo, while also addressing challenges related to medication access.

Panelists discuss how novel treatment mechanisms, efficacy assessments, and improved patient engagement strategies are shaping the evolving landscape of vitiligo management.

A review examined how vitiligo treatments aim to restore melanocyte function through grafting, phototherapy, immune regulation, antioxidants, and stem cell research.

Researchers behind the review suggested that future research should prioritize large-scale trials to confirm abrocitinib's long-term safety and efficacy in various skin disorders.

Researchers found that MBEHQ treatment increased oxidative stress and proinflammatory cytokines IL-1β and IL-18 in patients with vitiligo.

Catch up on the latest news on vitiligo advancements in 2024.

Panelists discuss how to address treatment challenges and manage site-specific concerns in vitiligo patients, drawing on expert insights and clinical experience.

Panelists discuss how phototherapy, combination treatments, and patient-centered strategies can be utilized to enhance quality of life for individuals with vitiligo.